Pharmacological treatment of HIV-associated pulmonary hypertension

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is a rare but severe disease that results from chronic obstruction of small pulmonary arteries, leading to right ventricular failure and, ultimately, death. One established risk factor for the development of PAH is HIV infection. The presence of PAH is an independent risk factor for mortality in HIV-infected patients. This article will focus on HIV-associated PAH (HIV-PAH) with special considerations to the available treatments. With the approval of the soluble guanylate cyclase stimulator riociguat, a new drug class has become available in addition to the already existing prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Guidelines for the treatment of idiopathic PAH and guidelines for antiretroviral therapy should be followed for the treatment of HIV-PAH.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalExpert Review of Clinical Pharmacology
DOIs
Publication statusAccepted/In press - Mar 3 2016

Fingerprint

Pulmonary Hypertension
HIV
Pharmacology
Guidelines
Phosphodiesterase 5 Inhibitors
Therapeutics
Rare Diseases
Pulmonary Artery
HIV Infections
Prostaglandins
Mortality
Pharmaceutical Preparations

Keywords

  • antiretroviral therapy
  • endothelin receptor antagonists
  • HIV
  • phosphodiesterase type 5 inhibitors
  • prostanoids
  • Pulmonary arterial hypertension
  • riociguat
  • therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{e31d8281fe5f4462aae51c9ccb7ae74f,
title = "Pharmacological treatment of HIV-associated pulmonary hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is a rare but severe disease that results from chronic obstruction of small pulmonary arteries, leading to right ventricular failure and, ultimately, death. One established risk factor for the development of PAH is HIV infection. The presence of PAH is an independent risk factor for mortality in HIV-infected patients. This article will focus on HIV-associated PAH (HIV-PAH) with special considerations to the available treatments. With the approval of the soluble guanylate cyclase stimulator riociguat, a new drug class has become available in addition to the already existing prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Guidelines for the treatment of idiopathic PAH and guidelines for antiretroviral therapy should be followed for the treatment of HIV-PAH.",
keywords = "antiretroviral therapy, endothelin receptor antagonists, HIV, phosphodiesterase type 5 inhibitors, prostanoids, Pulmonary arterial hypertension, riociguat, therapy",
author = "Pierangelo Chinello and Nicola Petrosillo",
year = "2016",
month = "3",
day = "3",
doi = "10.1586/17512433.2016.1151785",
language = "English",
pages = "1--11",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",

}

TY - JOUR

T1 - Pharmacological treatment of HIV-associated pulmonary hypertension

AU - Chinello, Pierangelo

AU - Petrosillo, Nicola

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Pulmonary arterial hypertension (PAH) is a rare but severe disease that results from chronic obstruction of small pulmonary arteries, leading to right ventricular failure and, ultimately, death. One established risk factor for the development of PAH is HIV infection. The presence of PAH is an independent risk factor for mortality in HIV-infected patients. This article will focus on HIV-associated PAH (HIV-PAH) with special considerations to the available treatments. With the approval of the soluble guanylate cyclase stimulator riociguat, a new drug class has become available in addition to the already existing prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Guidelines for the treatment of idiopathic PAH and guidelines for antiretroviral therapy should be followed for the treatment of HIV-PAH.

AB - Pulmonary arterial hypertension (PAH) is a rare but severe disease that results from chronic obstruction of small pulmonary arteries, leading to right ventricular failure and, ultimately, death. One established risk factor for the development of PAH is HIV infection. The presence of PAH is an independent risk factor for mortality in HIV-infected patients. This article will focus on HIV-associated PAH (HIV-PAH) with special considerations to the available treatments. With the approval of the soluble guanylate cyclase stimulator riociguat, a new drug class has become available in addition to the already existing prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Guidelines for the treatment of idiopathic PAH and guidelines for antiretroviral therapy should be followed for the treatment of HIV-PAH.

KW - antiretroviral therapy

KW - endothelin receptor antagonists

KW - HIV

KW - phosphodiesterase type 5 inhibitors

KW - prostanoids

KW - Pulmonary arterial hypertension

KW - riociguat

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84961214900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961214900&partnerID=8YFLogxK

U2 - 10.1586/17512433.2016.1151785

DO - 10.1586/17512433.2016.1151785

M3 - Article

AN - SCOPUS:84961214900

SP - 1

EP - 11

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

ER -